In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aroa Biosurgery

http://aroabio.com

Latest From Aroa Biosurgery

Hyperfine Says Question Is When, Not If, Portable MRI Will Impact The World; CEO Dave Scott Discusses

Hyperfine, which markets the first US FDA-cleared portable MRI system, is facing COVID-related headwinds in bringing its system to hospitals, but CEO Dave Scott says wider adoption of the disruptive solution is inevitable. The company is going public today after combining with the HealthCor Catalio Acquisition Corp.

Artificial Intelligence Clinical Trials

Puerto Rico Tax-Haven Status, R&D Credit Weakened By Tax-Reform Bill

Under tax reform legislation recently passed by Congress, a 20% tax on products made in domestic territories will adversely affect the many device firms with Puerto Rican plants that currently enjoy a lower, 4% tax rate on profits. And a second tax provision usually relied upon by medtech companies, the R&D tax credit, also loses ground under the final Senate bill passed Dec. 2.

Legislation United States

FDA 2012 Medical Device Quality-Related Warning Letters

Complete list of 103 domestic and 66 foreign device quality-related warning letters released in 2012.

Biologics: The Growth Engine In Advanced Wound Care

With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat. This article is reprinted from the June issue of Medtech Insight.

Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Mesynthes Ltd
UsernamePublicRestriction

Register